These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 31969170)

  • 1. Schistosomiasis vaccine development: update on human clinical trials.
    Molehin AJ
    J Biomed Sci; 2020 Jan; 27(1):28. PubMed ID: 31969170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative assessment of the impact of partially protective anti-schistosomiasis vaccines.
    Alsallaq RA; Gurarie D; Ndeffo Mbah M; Galvani A; King C
    PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005544. PubMed ID: 28410369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination or mass drug administration against schistosomiasis: a hypothetical cost-effectiveness modelling comparison.
    Collyer BS; Turner HC; Hollingsworth TD; Keeling MJ
    Parasit Vectors; 2019 Oct; 12(1):499. PubMed ID: 31647019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological Considerations for
    Driciru E; Koopman JPR; Cose S; Siddiqui AA; Yazdanbakhsh M; Elliott AM; Roestenberg M
    Front Immunol; 2021; 12():635985. PubMed ID: 33746974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schistosomiasis vaccines: where do we stand?
    Tebeje BM; Harvie M; You H; Loukas A; McManus DP
    Parasit Vectors; 2016 Sep; 9(1):528. PubMed ID: 27716365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccines for Human Schistosomiasis: Recent Progress, New Developments and Future Prospects.
    Molehin AJ; McManus DP; You H
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling the impact of a Schistosoma mansoni vaccine and mass drug administration to achieve morbidity control and transmission elimination.
    Kura K; Truscott JE; Toor J; Anderson RM
    PLoS Negl Trop Dis; 2019 Jun; 13(6):e0007349. PubMed ID: 31166956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sm-p80-Based Schistosomiasis Vaccine: Preparation for Human Clinical Trials.
    Siddiqui AA; Siddiqui SZ
    Trends Parasitol; 2017 Mar; 33(3):194-201. PubMed ID: 27865740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling control of Schistosoma haematobium infection: predictions of the long-term impact of mass drug administration in Africa.
    Gurarie D; Yoon N; Li E; Ndeffo-Mbah M; Durham D; Phillips AE; Aurelio HO; Ferro J; Galvani AP; King CH
    Parasit Vectors; 2015 Oct; 8():529. PubMed ID: 26489408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interrupting seasonal transmission of Schistosoma haematobium and control of soil-transmitted helminthiasis in northern and central Côte d'Ivoire: a SCORE study protocol.
    Tian-Bi YT; Ouattara M; Knopp S; Coulibaly JT; Hürlimann E; Webster B; Allan F; Rollinson D; Meïté A; Diakité NR; Konan CK; N'Goran EK; Utzinger J
    BMC Public Health; 2018 Jan; 18(1):186. PubMed ID: 29378542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Praziquantel for Schistosomiasis: Single-Drug Metabolism Revisited, Mode of Action, and Resistance.
    Vale N; Gouveia MJ; Rinaldi G; Brindley PJ; Gärtner F; Correia da Costa JM
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schistosomiasis in Egypt: A never-ending story?
    Othman AA; Soliman RH
    Acta Trop; 2015 Aug; 148():179-90. PubMed ID: 25959770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Policy implications of the potential use of a novel vaccine to prevent infection with Schistosoma mansoni with or without mass drug administration.
    Kura K; Collyer BS; Toor J; Truscott JE; Hollingsworth TD; Keeling MJ; Anderson RM
    Vaccine; 2020 Jun; 38(28):4379-4386. PubMed ID: 32418795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetylcholinesterase and Nicotinic Acetylcholine Receptors in Schistosomes and Other Parasitic Helminths.
    You H; Liu C; Du X; McManus DP
    Molecules; 2017 Sep; 22(9):. PubMed ID: 28906438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug Repurposing for Schistosomiasis: Combinations of Drugs or Biomolecules.
    Gouveia MJ; Brindley PJ; Gärtner F; Costa JMCD; Vale N
    Pharmaceuticals (Basel); 2018 Feb; 11(1):. PubMed ID: 29401734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morbidity control of schistosomiasis by mass drug administration: how can we do it best and what will it take to move on to elimination?
    Colley DG
    Trop Med Health; 2014 Jun; 42(2 Suppl):25-32. PubMed ID: 25425948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are We on Our Way to Achieving the 2020 Goals for Schistosomiasis Morbidity Control Using Current World Health Organization Guidelines?
    Toor J; Alsallaq R; Truscott JE; Turner HC; Werkman M; Gurarie D; King CH; Anderson RM
    Clin Infect Dis; 2018 Jun; 66(suppl_4):S245-S252. PubMed ID: 29860290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schistosomiasis vaccines.
    Hagan P; Sharaf O
    Expert Opin Biol Ther; 2003 Dec; 3(8):1271-8. PubMed ID: 14640953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Schistosoma mansoni infection and the therapeutic efficacy of praziquantel among school children in Manna District, Jimma Zone, southwest Ethiopia.
    Bajiro M; Dana D; Ayana M; Emana D; Mekonnen Z; Zawdie B; Garbi A; Kure A; Zeynudin A
    Parasit Vectors; 2016 Oct; 9(1):560. PubMed ID: 27772528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Still hope for schistosomiasis vaccine.
    Ricciardi A; Ndao M
    Hum Vaccin Immunother; 2015; 11(10):2504-8. PubMed ID: 26176659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.